Dassault Systèmes enters the next phase of the "Living Heart" project with AI-based virtual twinning * Matching and automation of virtual models of the heart, based on AI, will help simplify and accelerate medical device development processes
Dassault Systèmes today announced a beta trial to test a new generation of the “living heart” model, which is fully customizable for individual patients or patient populations. The trial aims to provide a level of customization and automation that makes the model a powerful tool that can simplify the research and development process for medical devices and accelerate regulatory testing and approval of new therapies.
The Living Heart project team is currently exploring highly personalized models that allow for the adjustment of tissue properties, structural variation, and other aspects – at the touch of a button. The new generation of the model is based on years of experience with real patients, and therefore the insights gained in it, about human physiology, make it possible to create thousands of virtual twins of a patient, which will be a reliable training set for generative artificial intelligence (Generative AI). Researchers and doctors will be able to understand diseases and predict how a patient population will respond to a particular treatment – without the need for human or animal experiments, and without restrictions on privacy or personal information.
“A decade ago, the Living Heart Project made history by debuting the first virtual twin of a human heart. Today, we are taking another giant leap forward with the next generation – a fully parametric, customizable simulation of the entire heart, enabling medical device companies to design, test and validate innovation faster and with greater confidence. This breakthrough, powered by the 3DEXPERIENCE platform, will help our customers reduce development costs, accelerate regulatory approvals and vastly improve the ability to predict how devices will fit with real patient anatomy – advancing personalized medicine at scale,” said Claire Butte, Vice President, Life Sciences and Healthcare Industry, Dassault Systèmes.
The beta trial of the new generation of the Living Heart project follows the publication of the ENRICHMENT Playbook, a guide for the medical device industry that explains how virtual twins can be used to accelerate clinical trials. The guide was published after a successful five-year collaboration with the U.S. Food and Drug Administration (FDA). The effectiveness of virtual twins and the potential to assist in validation will bring unprecedented benefits to the biopharmaceutical, hospital, medical device, wearable technology and public health industries – from reducing costs and accelerating regulatory approvals to improving patient outcomes.
Dassault Systèmes has established itself as a global leader in virtual twin technology in healthcare, drawing on decades of expertise in industrial applications and is now bringing this knowledge to medicine, clinical trials and patient care. The company announced the beta trial at 3DEXPERIENCE World in Houston, where it also presented new directions for expanding virtual twin applications to additional organs to address a wider range of medical challenges.
More of the topic in Hayadan:
